VIP

Overview and Mechanism of Action

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide belonging to the secretin/glucagon superfamily of peptide hormones, characterized by a conserved N-terminal helix and a C-terminal amide that are essential for receptor recognition and binding. VIP was first isolated from porcine small intestine by Said and Mutt in 1970 and named for its potent vasodilatory activity, though subsequent decades of research have revealed that VIP is among the most pleiotropic and evolutionarily conserved neuropeptides in the mammalian nervous system, with roles extending far beyond vascular tone regulation.

VIP exerts its biological effects through two G-protein-coupled receptors: VPAC1 (previously known as VIP1-R or VIPR1) and VPAC2 (VIP2-R or VIPR2), both Gs-protein-coupled receptors whose activation raises intracellular cAMP via adenylyl cyclase stimulation. A third receptor, PAC1, binds VIP with lower affinity but exhibits high affinity for pituitary adenylate cyclase-activating polypeptide (PACAP), VIP's close structural homologue. VPAC1 is expressed broadly — in the lung, liver, small intestinal epithelium, T lymphocytes, and throughout the central and peripheral nervous systems. VPAC2 expression is more restricted, predominating in the smooth muscle of the gastrointestinal tract, the pancreas, and specific brain regions including the suprachiasmatic nucleus (SCN).

The breadth of VIP's receptor distribution explains its wide-ranging physiological roles. In the gastrointestinal tract, VIP is a primary neurotransmitter of non-adrenergic non-cholinergic (NANC) inhibitory motor neurons, relaxing smooth muscle in the lower esophageal sphincter, pyloric sphincter, and the intestinal wall, and stimulating water and electrolyte secretion from intestinal epithelial cells. In the respiratory system, VIP induces bronchodilation and inhibits airway smooth muscle contraction, regulates mucosal secretion, and modulates pulmonary vasomotor tone. In the immune system, VIP acts as an anti-inflammatory mediator: it inhibits the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12) from macrophages and dendritic cells, promotes regulatory T cell differentiation, and has been proposed as an endogenous brake on excessive innate immune activation. In the SCN, VIP serves as a critical intercellular synchronization signal within the circadian clock network. In the nervous system broadly, VIP functions as a neurotrophic and neuroprotective factor, promoting neuronal survival and influencing synaptic plasticity.

Research History and Development

Following VIP's initial isolation and characterization, research through the 1970s and 1980s defined its distribution in the peripheral and central nervous systems (it is among the most abundant neuropeptides in the mammalian brain), its receptor pharmacology, and its roles in gastrointestinal physiology. The cloning of the VPAC1 and VPAC2 receptors in the 1990s provided molecular tools for systematic receptor pharmacology and enabled the development of VPAC-selective agonists and antagonists used as research tools.

Research interest in VIP's immune-modulatory properties intensified in the context of autoimmune disease models. Studies from Delgado, Ganea, and colleagues demonstrated that VIP administration attenuated disease severity in animal models of rheumatoid arthritis, multiple sclerosis (experimental autoimmune encephalomyelitis), Crohn's disease, and sepsis, positioning VIP as a candidate therapeutic for inflammatory conditions. Pulmonary hypertension research identified VIP deficiency in pulmonary arterial tissue from patients with idiopathic pulmonary arterial hypertension, leading to an inhaled VIP clinical trial. Clinical investigations have also examined VIP in the context of post-COVID syndrome, inflammatory bowel disease, and dry eye disease.

Typical Research Parameters

In cell culture immunology experiments, VIP is typically applied to macrophage, dendritic cell, or T lymphocyte cultures at concentrations of 10–100 nM to assess effects on cytokine production, proliferation, or differentiation. Receptor pharmacology experiments employ VPAC1- or VPAC2-expressing HEK-293 cell lines with cAMP accumulation as the primary functional readout. In vivo research in rodent models has used intraperitoneal, intranasal, or intravenous administration at doses of 0.5–10 nmol per animal, with outcomes including inflammatory biomarkers, disease score (in autoimmune models), bronchoconstriction parameters (in pulmonary models), and circadian phase markers (in SCN studies). VIP's short plasma half-life (~2 minutes due to DPP-IV and neutral endopeptidase degradation) necessitates careful consideration of administration timing and delivery method in in vivo paradigms. For research use only.

Storage Requirements

VIP as a lyophilized 28-amino-acid peptide should be stored at -20°C, protected from light and moisture. The peptide contains no disulfide bonds and is a linear chain, but its relatively large size (3326 Da) and amphipathic helical structure may predispose it to surface adsorption on plastic and glass surfaces — a known issue with neuropeptides. Carrier proteins (0.1% BSA) or silicone-coated low-binding tubes may be employed to minimize adsorption losses at low concentrations. Reconstituted solutions in physiological saline or 0.1% BSA-containing buffer should be stored at 2–8°C and used within 14 days. Avoid repeated freeze-thaw cycles.

Safety Notes and Research Considerations

VIP's potent vasodilatory activity means that systemic intravenous administration in animal models requires careful hemodynamic monitoring, as bolus injection can produce acute hypotension. The peptide's immunomodulatory effects on cytokine production should be considered in experimental designs where cytokine readouts are employed for other purposes. Surface adsorption at low concentrations (sub-nanomolar) may substantially reduce effective concentration in assay wells and animal dosing solutions unless carrier protein is included; researchers should verify effective concentrations using ELISA or radiolabeled VIP when working near detection limits. This material is for research purposes only.